PDSB Similar Chart Price Prediction
The price of PDSB is predicted to go up 32.56%, based on the high correlation periods with ASTL. The similarity of these two price pattern on the periods is 91.58%.
PDSB
ASTL
Up: 32.56%Similarity: 91.58%
PDSB Revenue Forecast
PDSB EPS Forecast
PDSB FAQs
What is bull’s view on PDSB?
What is bear's view on PDSB?
What is PDSB eps forecast for next quarter？
PDSB Analyst's Forecast
Kalpit Patel
B. Riley Securities
Strong Buy
2024-11-25
Price Target
$9 → $7
Upside
+222.58%
B. Riley lowered the firm's price target on PDS Biotechnology to $7 from $9 and keeps a Buy rating on the shares. The Q3 earnings update included a development plan revision for the registration-enabling Phase III VERSATILE-003 trial in HPV16-positive head and neck squamous cell carcinoma, with a sample size reduction from about 440 to roughly 350 patients while maintaining statistical power on the overall survival primary efficacy endpoint, the analyst tells investors in a research note. Management also acknowledged the potential impact of recent FDA approval of Keytruda in adjuvant and neoadjuvant HNSCC to be factored in this development plan revision, including via a recently commissioned survey of more than 50 oncologists treating HNSCC patients, the firm adds.
